Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.

about

Coconut Oil Extract Mitigates Testicular Injury Following Adjuvant Treatment with Antiretroviral Drugs.

P2860

Q37367561-205E13E8-E85A-4D9F-875C-026D86FC9605

P2860

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.

Item

http://www.wikidata.org/entity/Q40784890

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Liver toxicity and risk of dis ...... : influence of liver fibrosis.

@en

type

Item

label

Liver toxicity and risk of dis ...... : influence of liver fibrosis.

@en

prefLabel

Liver toxicity and risk of dis ...... : influence of liver fibrosis.

@en

P1476

Liver toxicity and risk of dis ...... : influence of liver fibrosis.

@en

P2093

A Castro

http://www.w3.org/2001/XMLSchema#string

A Mena

http://www.w3.org/2001/XMLSchema#string

A Moreno

http://www.w3.org/2001/XMLSchema#string

C Quereda

http://www.w3.org/2001/XMLSchema#string

J Pedreira

http://www.w3.org/2001/XMLSchema#string

S Bañón

http://www.w3.org/2001/XMLSchema#string

S Moreno

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population

Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

The importance of drug-drug interactions in the DAA era.

Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.

P304

62-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIV.12274

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

J L Casado

P577

2015-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279630085

http://www.w3.org/2001/XMLSchema#string

P698

26122981

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.

about

P2860

P2860

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921